Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study.
Novel hypoxic cell radiosensitiser doranidazole was tested for unresectable pancreatic cancer administered at intraoperative radiotherapy. Short-term survival was not different. However, difference has been observed concerning 3-year survival (doranidazole group vs. placebo; 23% vs. 0%, p=0.0192). This sensitiser might be effective in improving long-term survival for pancreatic cancer.
Karasawa
Katsuyuki
K
Department of Radiology, Tokyo Metropolitan Komagome Hospital, Japan. karasawa@cick.jp
Sunamura
Makoto
M
Okamoto
Atsutake
A
Nemoto
Kenji
K
Matsuno
Seiki
S
Nishimura
Yasumasa
Y
Shibamoto
Yuta
Y
D000328:Adult; D000368:Aged; D015687:Cell Hypoxia; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate
D007093:Imidazoles; D011838:Radiation-Sensitizing Agents; C106738:doranidazole